Society for Industrial Microbiology and Biotechnology

The Society for Industrial Microbiology and Biotechnology (SIMB) is a nonprofit, international association dedicated to the advancement of microbiological sciences, especially as they apply to industrial products, biotechnology, materials, and processes. Founded in 1949, SIMB promotes the exchange of scientific information through its meetings and publications, and serves as liaison among the specialized fields of microbiology. Membership in the Society is extended to all scientists and companies in the general field of microbiology.

Related News

RESEARCH

TURTLETREE AND SOLAR BIOTECH ENTER STRATEGIC PARTNERSHIP

TurtleTree | August 16, 2021

news image

Solar Biotech, led by industrial biotech expert Alex Berlin, has become a significant piece of the puzzle for sustainable food tech companies taking products to market. TurtleTree knew from the beginning that one of the biggest challenges for food tech companies was developing the technologies required to scale up bio-manufacturing processes. TurtleTree is a biotech company based in Singapore and the US. The company is focused on providing access to the best nutrients in milk usin...

Read More

MEDTECH

IBM RESEARCH AND ARCTORIS ACCELERATE CLOSED LOOP DRUG DISCOVERY WITH AI AND CLOUD

Arctoris | September 14, 2021

news image

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Opt...

Read More

CELL AND GENE THERAPY

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

news image

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More

INDUSTRY OUTLOOK

CUROCELL, BREAKS GROUND ON 'CAR-T MANUFACTURING GMP FACILITY'

Curocell, Inc. | December 24, 2021

news image

Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 has recently broken ground for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt. The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-meter site of CAR-T Center. By the first half of 2023, construction is expected to be completed and...

Read More
news image

RESEARCH

TURTLETREE AND SOLAR BIOTECH ENTER STRATEGIC PARTNERSHIP

TurtleTree | August 16, 2021

Solar Biotech, led by industrial biotech expert Alex Berlin, has become a significant piece of the puzzle for sustainable food tech companies taking products to market. TurtleTree knew from the beginning that one of the biggest challenges for food tech companies was developing the technologies required to scale up bio-manufacturing processes. TurtleTree is a biotech company based in Singapore and the US. The company is focused on providing access to the best nutrients in milk usin...

Read More
news image

MEDTECH

IBM RESEARCH AND ARCTORIS ACCELERATE CLOSED LOOP DRUG DISCOVERY WITH AI AND CLOUD

Arctoris | September 14, 2021

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Opt...

Read More
news image

CELL AND GENE THERAPY

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More
news image

INDUSTRY OUTLOOK

CUROCELL, BREAKS GROUND ON 'CAR-T MANUFACTURING GMP FACILITY'

Curocell, Inc. | December 24, 2021

Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 has recently broken ground for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt. The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-meter site of CAR-T Center. By the first half of 2023, construction is expected to be completed and...

Read More